<DOC>
	<DOCNO>NCT00146913</DOCNO>
	<brief_summary>Sixty % CML patient treat Imatinib mesylate achieve major cytogenetic response ( CCR ) 18 month . So , 40 % patient must receive additional treatment . In vitro , show IM Interféron-alpha synergic anti-proliferative effect chromosome Ph+ cell line . By use Peg-Interféron IM combination , hope increase cytogenetic response patient .</brief_summary>
	<brief_title>AFR10 - Combination Therapy Imatinib Mesylate ( IM ) + Alpha-2A Interferon Chronic Phase CML Patients Resistant Refractory IM Used Single Therapy Least One Year</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Chronic phase Philadelphia positive CML , confirm karyotyping ( FISH ) analysis , complete hematologic response IM . Lack major cytogenetic response least one year STI 571 single therapy . Male female * 18 year old . Informed consent sign . Performance status grade 0 2 ( ECOG ) . SGOT SGPT &lt; 3N Serum bilirubin &lt; 1.5 N Serum creatinine &lt; 1.5 N No HSC graft plan BHCG negative female potential childbearing Absence complete hematologic response Extramedullar involvement Previous extrahematologic intolerance Interféron dose superior equal 25 MUI/week Depressive syndrome control Not control dysthyroidy Autoimmune pathology control Women childbearing potential unwilling unable use adequate method avoid pregnancy entire period study Significant cardiac disease ( grade 3 ) Known seropositivity HIV Active viral hepatitis Other malignant disease Other experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Chronic myeloid leukaemia</keyword>
	<keyword>resistant</keyword>
	<keyword>refractory</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>